IL17A and neoplasm: Cisplatin treatment could restore the splenic immunophenotype downregulating CD44+, IL-17A+ MDSCs presumably because of the smaller tumor burden, on the other hand MDSCs are also sensitive to low dose chemotherapy due to their high proliferative potential [30].